NR1H4 and metabolic dysfunction-associated steatotic liver disease: For example, the synthetic FXR agonist Px‐102/Px‐10479 (and the follow‐up compound GS‐9674) is being tested in a phase IIa randomized, clinical trial in patients with NAFLD (ClinicalTrials.gov identifier: NCT01999101), and the selective and highly potent WAY‐362450/FXR‐450 compound is in early‐phase clinical development (ClinicalTrials.gov identifier: NCT00499629).